Evaluation Study of SPOTme® Skin Cancer Screenings

Skin Cancer Clinical Trial

Official title:

Evaluation Study of SPOTme® Skin Cancer Screenings

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03564769
• Other study ID #: 17-1668
• Status: Completed
• Phase: N/A
• Start date: December 1, 2017
• Est. completion date: June 1, 2019

Study information

• Verified date: August 2019
• Source: Harvard School of Public Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Description:

Despite tremendous growth in both the interest and volume of skin cancer screenings at the national level, the actual utility and impact of the AAD SPOT me™ skin cancer screening programs have not been fully evaluated. This study will address this knowledge gap. Early detection is vital in the fight against skin cancer, the most common cancer in the United States. While the effects of skin cancer can be devastating, this disease is highly treatable when detected early.

This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 431
• Est. completion date: June 1, 2019
• Est. primary completion date: October 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participated in the American Academy of Dermatology national screening program in 2016 or 2017

• Have a presumptive diagnosis (screening, non-confirmed) of melanoma

• Have provided the AAD with permission to be re-contacted

• Have provided the AAD with an email address

• Aged 18 years or older

• Able to read English

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Skin Cancer
• Skin Neoplasms

Intervention

Behavioral:
• Intervention Arm
Individuals randomized to the intervention group will receive skin cancer screening educational materials.

Other:
• AAD SPOTme? skin cancer screening
All study participants will have participated in the AAD SPOTme? skin cancer screening program in either 2016 or 2017.

Locations

Country	Name	City	State
United States	Harvard TH Chan School of Public Health	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Harvard School of Public Health	American Academy of Dermatology (AAD)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Completion of a physician skin examination	Self-report of a physician skin examination will be defined as a health care provider examining the patient's entire body for any sign of skin cancer during the period following patient's receipt of an AAD SPOTme® skin cancer screening to the baseline assessment.	Baseline
Secondary	Completion of a physician skin examination	Self-report of a physician skin examination will be defined as a health care provider examining the patient's entire body for any sign of skin cancer during the 3 months prior to the 6-month follow up assessment	6 months
Secondary	Patient thorough skin self-examination (TSSE)	Self-report of patient thorough skin self-examination (TSSE) will be defined as performing at least one TSSE during the 3 months prior to the 6-month follow up assessment	6 months
Secondary	Patient attitude towards sun protection	Self-report of patient attitude towards use of sun protection will be defined by likelihood of engaging in sun protection practices in the year following the 6-month follow up assessment	6 months